Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL18249967 | 1.00 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1537211 | 1.00 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL302977 | 1.00 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL3170725 | 0.97 | SLC7A5 (0.73) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL2205393 | 0.97 | SLC7A5 (0.73) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL11338506 | 0.95 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL11338514 | 0.95 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL23201519 | 0.94 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL27468643 | 0.94 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL22042334 | 0.93 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108653746-B | Multi-drug-loading-point high-drug-loading-rate ligand drug conjugate | 北京键凯科技股份有限公司 | 2021-04-27 | — | — | CN | claimed |
| CN-110327248-A | A kind of composition and manufacture craft of no silicone oil conditioning hair | 广州优敏泉生物科技有限公司 | 2019-10-15 | — | — | CN | claimed |
| JP-4849764-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| WO-2002000687-A9 | ANTIMICROBIAL PEPTIDES AND METHODS OF USE THEREOF | UNIV BRITISH COLUMBIA (CA) | 2003-09-18 | — | — | WO | claimed |
| EP-1294745-A2 | ANTIMICROBIAL PEPTIDES AND METHODS OF USE THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2003-03-26 | — | — | EP | claimed |
| US-6337317-B1 | AMINO ACID SEQUENCE PEPTIDES AS MICROBIOCIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-01-08 | — | — | US | claimed |
| WO-2002000687-A2 | ANTIMICROBIAL PEPTIDES AND METHODS OF USE THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-01-03 | — | — | WO | claimed |
| EP-0368920-A1 | LECTINES FIXING BETA-D-GALACTOSIDE. | IDEON CORP (US) | 1990-05-23 | — | — | EP | claimed |
| WO-1989000581-A1 | LECTINES FIXING BETA-D-GALACTOSIDE | IDEON CORPORATION (US) | 1989-01-26 | — | — | WO | claimed |
| EP-0210257-A4 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS. | HURWITZ CHARLES (US) | 1988-01-20 | — | — | EP | claimed |
| EP-0210257-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ, Charles (US) | 1987-02-04 | — | — | EP | claimed |
| WO-1986004588-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ CHARLES (US) | 1986-08-14 | — | — | WO | claimed |
| US-12042530-B2 | Target peptides for immunotherapy and diagnostics | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230025608-A1 | TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220211828-A1 | TARGET PEPTIDES FOR OVARIAN CANCER THERAPY AND DIAGNOSTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-07-07 | — | — | US | disclosed |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| EP-0500589-A1 | PURIFIED PROTEIN AND BIOACTIVE PHARMACEUTICAL. | ALFACELL CORP (US) | 1992-09-02 | — | — | EP | disclosed |
| WO-1991007435-A1 | PURIFIED PROTEIN AND BIOACTIVE PHARMACEUTICAL | ALFACELL CORPORATION (US) | 1991-05-30 | — | — | WO | disclosed |
| EP-0368920-A1 | LECTINES FIXING BETA-D-GALACTOSIDE. | IDEON CORP (US) | 1990-05-23 | — | — | EP | disclosed |
| WO-1989000581-A1 | LECTINES FIXING BETA-D-GALACTOSIDE | IDEON CORPORATION (US) | 1989-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | SLC7A5 2004/4885PTGS1 4814/4885ALPI 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.